Bronchogen 20mg
Research-grade Bronchogen 20mg. 99% purity, third-party tested with published COA.
Ships from USA
1–3 day delivery
Free Shipping
On orders $150+
Peptide Handling & Storage Guide
Storage temperature, shelf life & reconstitution (PDF)
99%+ Purity
COA included
Same-Day Shipping
Orders before 2PM EST
Secure Checkout
SSL encrypted
Shipment Protection
Lost or damaged — reshipped free
Compound Information
- Type
- Synthetic tetrapeptide bioregulator
- Molecular Formula
- C18H30N4O9
- Molecular Weight
- 446.5 g/mol
- Purity
- 99%
- Sequence
- Ala-Glu-Asp-Leu (AEDL)
Reference chemistry (free base) from public chemical databases and peer-reviewed literature. For laboratory research identification only.
Research Use Only. This vial is bound for the lab bench — supplied for in-vitro scientific work exclusively, never for administration to any person or animal.
About Bronchogen
Bronchogen is a four-residue peptide, Ala-Glu-Asp-Leu (AEDL, ~C18H30N4O9), one of the short synthetic "peptide bioregulators" developed by V. Kh. Khavinson and colleagues. Some primary Khavinson-group papers write the sequence as Ala-Asp-Glu-Leu (ADEL); the two notations refer to the same named compound but disagree on the order of the internal glutamic- and aspartic-acid residues.
Published preclinical studies report a DNA-stabilizing effect (raising the melting temperature of isolated DNA) in a biophysical assay, modulation of proliferation- and differentiation-related genes and proteins in cultured human bronchial epithelial cells, and reduced airway-remodeling features in a rat model of obstructive lung pathology. The evidence is small and dominated by a single research group; there are no published human clinical trials, and it has no regulatory approval for human use.
Frequently Asked Questions
What is Bronchogen?
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, AEDL) in the Khavinson class of short peptide bioregulators, associated in that framework with bronchial/respiratory tissue. It is sold for laboratory research use only and has been examined solely in preclinical studies.
What is Bronchogen peptide?
It is a four-amino-acid peptide of alanine, glutamic acid, aspartic acid, and leucine. In the research literature it has been studied for its interaction with DNA and its effects on gene and protein expression in bronchial epithelial cell cultures and in a rat lung-pathology model. Research use only.
What is the sequence of Bronchogen?
The commonly cited sequence is Ala-Glu-Asp-Leu (AEDL). Note that some primary publications write it as Ala-Asp-Glu-Leu (ADEL); the notations refer to the same named compound but differ on the internal Glu/Asp order.
What research has been done on Bronchogen?
Published studies are preclinical: a biophysical study of the peptide’s DNA-stabilizing effect, a study of gene and protein expression in cultured human bronchial epithelial cells, and a rat model of obstructive lung pathology. All findings are from cell-culture or animal models and do not demonstrate any effect in humans.
Is Bronchogen approved for human use?
No. Bronchogen is not approved by any comparable regulatory authority for human use, and there are no published human clinical trials. It is intended for laboratory research use only.
Research & References
Independent databases and peer-reviewed literature for Bronchogen. Provided for research reference only.
External resources are independent and not affiliated with or endorsed by PHIOGEN. Listed for laboratory research reference only.
